Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Shivom Raises $32M in Presale to Create Genomic Data Pool on Blockchain

Published 05/04/2018, 02:10 AM
Updated 05/04/2018, 02:31 AM
 Shivom Raises $32M in Presale to Create Genomic Data Pool on Blockchain

Shivom is a unique project with the ambitious goal of creating the world's largest genomic data hub, giving biotechnology experts, healthcare industry participants, and state-backed research institutions the chance to collaborate and make discoveries in the domain of medicine. Besides offering a comprehensive solution for patients and genome data donors, the Shivom platform provides a blockchain-based marketplace for medical service providers and researchers.

The team has just closed the private sale and pre-sale rounds, raising $32 million. With the main open ICO round starting on May 3, the project is likely to reach its hard cap of $35 million.

Currently, 7.6 billion people inhabit the Earth, each with a unique genome code - a combination of genes that determines their appearance, health, and other distinguishing characteristics. Scientists have been working for decades to decipher this code, so far with no success.

Genomic data is controlled by the heavyweight players, and this monopoly is considered the key obstacle to research progress. The dominant companies profit from selling genomic data to third parties and do not even bother to inform the data donors that their information has been shared. Donors have no guarantees their data is protected from hackers and unauthorized access.

The decentralized technologies utilized in Shivom's platform will democratize the processes of sharing and using genome data, while smart contracts will ensure that all information shared on the platform is anonymous and secure. Users will be motivated to share their data through monetary remuneration in the form of OmiX token.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Another significant hurdle is the lack of data diversity. DNA kits are unaffordable for the majority of the population, which means that the genomic data available in public databases comes from wealthy people, mostly from Western Europe and North America. Such a statistical imbalance makes genome interpretation less accurate and less comprehensive as the data sets available to the biomedical community do not cover the whole range of natural human variation.

Shivom aims to bring the technology to developing countries and underrepresented population segments.

Apart from $32 million of investments secured in the private sale and pre-sale rounds, Shivom is proud to expand its advisory board with the addition of Taavi Roivas, former Estonian Prime Minister and acting member of the Estonian Parliament. Roivas actively promotes the digital development of governmental and corporate sectors and supports many innovative and progressive initiatives, including digital citizens rights, e-citizenship, and e-voting. Collinstar Capital, Hoperidge Capital, DigitalX, Ironside Capital, and Discovery Capital are other prominent investors in Shivom.

“The past few weeks have been filled with positive growth for Shivom,” co-Founder and CEO Dr. Axel Schumacher said. “The first round of funding will allow us to propel Shivom into action, as will our recent partnerships and the addition of former Estonian Prime Minister Taavi Roivas to the advisory board. We are looking forward to completing our public token sale and creating additional strong partnerships in the near future.”


This article appeared first on Cryptovest

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.